Gut Inflammation Capsules are an encapsulated, multi-component research formulation containing BPC-157, KPV, palmitoylethanolamide (PEA), and Tributyrin. Each compound retains its individual chemical identity within the formulation. The product is supplied exclusively for controlled laboratory analysis, method development, and in-vitro research.
This formulation is intended for qualified researchers evaluating multi-component samples within controlled analytical environments. Relevant research activities may include identity confirmation, constituent characterization, stability testing, comparative assay development, and the evaluation of predefined molecular or biochemical endpoints.
Because this product contains multiple research compounds, it does not have a single molecular formula, molecular weight, CAS number, or peptide sequence. Researchers should consult the applicable lot-specific Certificate of Analysis and supporting product documentation for available specifications and analytical results.
NordSci provides independently generated, lot-specific analytical documentation for product identity and quality verification. Available testing records and Certificates of Analysis can be accessed through the product page or COA Library.
All products are produced using lyophilization (freeze-drying), a preservation method that allows peptides to remain fully stable during shipping for approximately 3-4 months. Once a peptide has been reconstituted with bacteriostatic water, it must be refrigerated to maintain integrity. After reconstitution, peptides typically remain stable for up to 30 days when stored properly.
Lyophilization, also referred to as cryodesiccation, is a specialized dehydration process in which peptides are first frozen and then exposed to a low-pressure environment. This causes the water within the vial to transition directly from a solid to a vapor (sublimation), leaving behind a dry, crystalline white material known as a lyophilized peptide. In this powdered form, peptides may be safely stored at room temperature until they are ready to be reconstituted with bacteriostatic water.
After delivery, peptides should be protected from heat and light. If use is expected within the near future (whether days, weeks, or a few months) refrigerated storage below 4°C (39°F) is generally sufficient. Lyophilized peptides are commonly stable at room temperature for several weeks or longer, making short-term ambient storage acceptable when use is anticipated within that timeframe.
For extended storage, ranging from several months to multiple years, freezing is strongly recommended. Storage at -80°C (-112°F) offers optimal long-term stability and helps preserve peptide structure and quality over time.
For more detailed guidance on peptide handling and storage best practices, please refer to the resource below:
Gut Inflammation Capsules are an encapsulated, multi-component research formulation containing BPC-157, KPV, palmitoylethanolamide (PEA), and Tributyrin. Each compound retains its individual chemical identity within the formulation. This product is supplied exclusively for controlled laboratory analysis, method development, and in-vitro research.
The formulation is intended for qualified researchers evaluating multi-component samples under controlled analytical conditions. Applicable laboratory activities may include identity confirmation, constituent characterization, stability testing, comparative assay development, and the measurement of predefined molecular or biochemical endpoints.
Because this product contains multiple research compounds, the complete formulation does not have a single molecular formula, molecular weight, CAS number, or peptide sequence. Researchers should consult the applicable lot-specific Certificate of Analysis and supporting documentation for available specifications and analytical results.
Gut Inflammation Capsules – Research Specifications:
| Product Name | Gut Inflammation Capsules |
| Format | Encapsulated research formulation |
| Formula Components | BPC-157, KPV, PEA, and Tributyrin |
| Chemical Classification | Multi-component formulation containing peptide and non-peptide research compounds |
| Molecular Formula | No single molecular formula applies to the complete formulation |
| Molecular Weight | No single molecular weight applies to the complete formulation |
| CAS Number | No single CAS number applies to the complete formulation |
| Peptide Sequence | Component-specific; consult available technical documentation |
| Appearance | Capsule format |
| Purity / Identity | Refer to the lot-specific Certificate of Analysis for applicable analytical documentation |
| Storage Conditions | Store sealed in a cool, dry environment protected from heat, direct light, humidity, and moisture |
| Research Use Only | Supplied exclusively for controlled laboratory research. Not for human or animal consumption or in-vivo use. |
Gut Inflammation Capsules are a multi-component laboratory material designed for controlled analytical and in-vitro research. The formulation combines two peptide-based compounds with two chemically distinct non-peptide compounds, allowing qualified researchers to examine the material using predefined laboratory methods.
BPC-157 and KPV are peptide-based research compounds. PEA is a fatty acid amide, while Tributyrin is a triacylglycerol compound. The inclusion of chemically distinct constituents requires researchers to select analytical procedures appropriate for each component and the formulation as a whole.
Research involving multi-component formulations requires carefully defined controls because each constituent can introduce separate analytical variables. Suitable study designs may include validated reference standards, negative and positive controls, predetermined assay conditions, documented sample-preparation procedures, and component-specific analytical methods.
Researchers conducting comparative analytical work with an individual component may also review BPC-157. Parallel evaluation of individual reference materials may assist laboratories with method specificity, constituent attribution, stability assessment, and matrix-effect analysis.
Important Research Notice: Lot-specific Certificates of Analysis provide the applicable analytical documentation for the supplied research material. Researchers should verify product identity, lot information, storage requirements, and available test results before beginning laboratory work.
THIS PRODUCT IS INTENDED EXCLUSIVELY FOR LABORATORY RESEARCH. NOT FOR HUMAN OR ANIMAL CONSUMPTION. NOT FOR IN-VIVO, CLINICAL, VETERINARY, DIAGNOSTIC, THERAPEUTIC, PREVENTIVE, FOOD, DRUG, DIETARY-SUPPLEMENT, OR COSMETIC USE.
This formulation may be evaluated in controlled in-vitro assay systems designed to measure predefined biochemical or molecular endpoints associated with gastrointestinal research models. Experimental interpretation should remain limited to the validated scope and limitations of the selected assay.
The material must not be used to make claims regarding human gastrointestinal function, symptom relief, barrier restoration, disease management, or therapeutic outcomes.
Qualified laboratories may use the formulation in controlled in-vitro experiments involving predefined signaling markers or assay targets. Appropriate controls are required to distinguish formulation-level observations from measurements associated with individual constituents or the experimental matrix.
Findings from laboratory assays must not be interpreted as evidence that the product changes inflammation, immune function, infection response, or disease outcomes in humans or animals.
Tributyrin may be examined as an individual constituent within analytical or in-vitro research involving predefined metabolite-related measurements. Experimental procedures should account for matrix composition, compound stability, assay specificity, reference standards, and the limitations of the selected model.
This research context does not establish suitability for dietary, nutritional, microbiome, gastrointestinal, clinical, or therapeutic use.
The formulation may be used in comparative laboratory designs that evaluate a multi-component sample alongside individual reference compounds, vehicle controls, or other defined research materials. This approach may assist with analytical attribution and method validation when supported by suitable controls.
Laboratories should document sample identity, preparation procedures, analytical conditions, instrument settings, acceptance criteria, and protocol deviations to maintain traceability and reproducibility.
Gut Inflammation Capsules should be handled only by qualified personnel in an appropriately equipped laboratory. Researchers should follow applicable institutional requirements, chemical-hygiene procedures, personal-protective-equipment policies, and material-handling SOPs.
Keep the original container sealed when it is not being accessed. Record the product lot number, receipt date, storage location, and handling history in laboratory documentation. Prevent cross-contamination by using clean equipment and designated work areas appropriate for the analytical procedure.
The capsule presentation is a research-material format and must not be interpreted as a consumer dosage form. Do not consume, administer, dispense, prescribe, compound, or apply the material to humans or animals. NordSci does not provide dosing, administration, injection, consumption, or clinical-application guidance.
Protocol Design Considerations: Multi-component research materials may produce matrix effects or overlapping analytical signals. Researchers should use appropriate controls, validated methods, predefined acceptance criteria, and constituent-specific reference materials when necessary.
Note: This information is provided solely to identify the product and describe permissible laboratory research contexts. All research must be performed by qualified personnel in accordance with applicable laws, institutional policies, and laboratory procedures.
Each available lot of Gut Inflammation Capsules is accompanied by analytical documentation identifying the tested research material and reporting applicable quality parameters. The Certificate of Analysis should be matched to the lot number displayed on the product container.
COA documentation may be used to support laboratory procurement, receiving inspection, material identification, quality-control review, and research traceability. Researchers remain responsible for determining whether the documented specifications are appropriate for their intended analytical method.
Testing methods and reported results may vary by product and lot. Consult the applicable certificate for the specific analytical methods, specifications, and results associated with the supplied material.
Gut Inflammation Capsules are available from NordSci Peptides exclusively as a laboratory research material. Procurement teams should review the product label, lot-specific Certificate of Analysis, storage information, and institutional requirements before ordering or accepting the material.
The product is not a drug, dietary supplement, food, cosmetic, medical product, or veterinary product. Its capsule format does not indicate suitability for consumption or administration.
IMPORTANT: Gut Inflammation Capsules are supplied exclusively for controlled laboratory research. They are not approved for human or animal consumption, in-vivo procedures, clinical use, veterinary use, diagnosis, treatment, disease prevention, food use, dietary-supplement use, or cosmetic use. Purchasers and researchers are responsible for compliance with all applicable laws, regulations, institutional policies, and laboratory requirements.
